Surgical Management of Oligometastatic Non-Small Cell Lung Cancer

Michael Lanuti

doi:10.1016/j.thorsurg.2016.04.002

Surgical Management of Oligometastatic Non-Small Cell Lung Cancer

Thorac Surg Clin. 2016 Aug;26(3):287-94. doi: 10.1016/j.thorsurg.2016.04.002.

Author

Michael Lanuti¹

Affiliation

¹ Division of Thoracic Surgery, Harvard Medical School, Massachusetts General Hospital, 55 Fruit Street, Blake 1570, Boston, MA 02114, USA. Electronic address: MLanuti@mgh.harvard.edu.

PMID: 27427523
DOI: 10.1016/j.thorsurg.2016.04.002

Abstract

Patients harboring stage IV non-small cell lung cancer represent a heterogeneous population with limited life expectancy. Targeted chemotherapy and immunotherapy have improved median survival for a minority of patients. A subset of patients with solitary foci of metastatic disease appears to have improved survival compared to others with stage IV NSCLC. The role of aggressive local control with curative intent for all disease sites in synchronous oligometastatic disease lacks randomized data; however, published retrospective series from single institutions suggest improved survival in highly selected patients (11-30%, 5-year survival) with low morbidity and mortality < 2%.

Keywords: Metastases; Metastectomy; Non–small lung cancer; Oligometastases; Surgery.

Publication types

Review

MeSH terms

Carcinoma, Non-Small-Cell Lung / secondary*
Carcinoma, Non-Small-Cell Lung / surgery*
Disease Management*
Humans
Lung Neoplasms / pathology*
Lung Neoplasms / surgery*
Neoplasm Metastasis
Pneumonectomy / methods*